Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Equity Average (2016 - 2025)

Historic Equity Average for Ocular Therapeutix (OCUL) over the last 12 years, with Q4 2025 value amounting to $456.3 million.

  • Ocular Therapeutix's Equity Average rose 3673.76% to $456.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $456.3 million, marking a year-over-year increase of 3673.76%. This contributed to the annual value of $484.8 million for FY2025, which is 13855.19% up from last year.
  • Per Ocular Therapeutix's latest filing, its Equity Average stood at $456.3 million for Q4 2025, which was up 3673.76% from $282.1 million recorded in Q3 2025.
  • Over the past 5 years, Ocular Therapeutix's Equity Average peaked at $456.3 million during Q4 2025, and registered a low of $5.5 million during Q3 2023.
  • Over the past 5 years, Ocular Therapeutix's median Equity Average value was $83.8 million (recorded in 2021), while the average stood at $166.3 million.
  • As far as peak fluctuations go, Ocular Therapeutix's Equity Average surged by 1365919.54% in 2021, and later crashed by 9121.0% in 2023.
  • Ocular Therapeutix's Equity Average (Quarter) stood at $87.7 million in 2021, then crashed by 53.46% to $40.8 million in 2022, then increased by 21.29% to $49.5 million in 2023, then skyrocketed by 574.22% to $333.7 million in 2024, then surged by 36.74% to $456.3 million in 2025.
  • Its Equity Average was $456.3 million in Q4 2025, compared to $282.1 million in Q3 2025 and $285.9 million in Q2 2025.